A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2010-02-13
Target enrollment:
Participant gender:
Summary
This single arm, open label study will assess the safety and efficacy, with regard to
reduction of signs and symptoms,of treatment with tocilizumab in patients with moderate to
severe active rheumatoid arthritis. Patients will receive tocilizumab 8 mg/kg IV every 4
weeks for a total of 6 infusions. Patients already receiving methotrexate at entry into the
study may continue with their treatment together with tocilizumab.The anticipated time on
study treatment is 3-12 months, and the target sample size is <100 individuals.